<SEC-DOCUMENT>0001104659-20-050023.txt : 20200423
<SEC-HEADER>0001104659-20-050023.hdr.sgml : 20200423
<ACCEPTANCE-DATETIME>20200423084208
ACCESSION NUMBER:		0001104659-20-050023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200423
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200423
DATE AS OF CHANGE:		20200423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEAP THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001509745
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				274412575
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37990
		FILM NUMBER:		20809256

	BUSINESS ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617 252 4343

	MAIL ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dekkun Corp
		DATE OF NAME CHANGE:	20110107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2016685d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(D)</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>April&nbsp;23, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leap Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="text-align: center; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-37990</B></FONT></TD>
    <TD STYLE="text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27-4412575</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="background-color: white">47
Thorndike Street, Suite&nbsp;B1-1<BR>
 Cambridge, MA</FONT></B></FONT></TD>
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>02141</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Registrant&rsquo;s telephone number, including area code: <B>(617)&nbsp;714-0360</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B>  <B>N/A</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Former name or former address, if changed since last report) <B></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written
communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17&nbsp;CFR 240.14d-2(b)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17&nbsp;CFR 240.13e-4(c)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Title of each class</TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Trading Symbol(s)</TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Common Stock, par value $0.001</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">LPTX</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Nasdaq Global Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Item 8.01.</B></TD><TD STYLE="text-align: justify"><B>Other Events</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;23, 2020, Leap Therapeutics,&nbsp;Inc.
(the &ldquo;Company&rdquo;) issued a press release entitled &ldquo;Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy
and Paclitaxel Combination in Gynecologic Cancers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The full text of the press release is filed
as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K and incorporated herein by reference; provided, however that information
on or connected to our website referenced in the Company&rsquo;s press release is expressly not incorporated by reference into
or intended to be filed as a part of this Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 10%"><B>Exhibit<BR> Number</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 89%"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm2016685d1_ex99-1.htm">99.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm2016685d1_ex99-1.htm">Press Release dated April&nbsp;23, 2020.</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- 2 -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>LEAP THERAPEUTICS,INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April&nbsp;23, 2020</FONT></TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Douglas E. Onsi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>Douglas E. Onsi</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2016685d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 5.5in"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 5.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2016685d1_ex99-1img001.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leap Therapeutics to Present Updated
Data for DKN-01 Monotherapy and Paclitaxel Combination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>In Gynecologic Cancers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Enhanced Survival Outcomes Achieved in Patients with Wnt Activating Mutations and DKK1-high Tumors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>DKN-01 Monotherapy Treated Endometrial Cancer Patient Maintains a Complete Response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Responses Observed in Carcinosarcoma Patients Treated with DKN-01 Plus Paclitaxel Combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Conference Call and Webcast to be Held April 23, 2020 at 8:30 A.M. EDT</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cambridge, MA &ndash; April 23, 2020</B>
 &ndash; Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics,
today announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as
both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies. Leap will
host a conference call with Rebecca Arend, M.D., Assistant Professor and Associate Scientist, Gynecologic Oncology Clinic, The
University of Alabama at Birmingham School of Medicine Comprehensive Cancer Center Experimental Therapeutics Program, today, April
23, 2020, at 8:30 A.M. EDT to discuss the data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are seeing clinically meaningful
monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response,
a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable
responses and disease control in paclitaxel-experienced patients,&rdquo; said Dr. Arend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This study also demonstrates the
importance of mechanism of action based biomarkers for DKN-01 therapy, as patients with high tumor DKK1 expression or Wnt activating
mutations had enhanced progression-free survival and overall survival. These biomarkers should be the foundation for additional
DKN-01 studies in endometrial and carcinosarcoma patients, as monotherapy and in combination with other active agents,&quot; continued
Dr. Arend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The P204 Study in Gynecologic Cancers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The P204 study is a Phase 2 basket study
evaluating DKN-01 as a monotherapy and in combination with paclitaxel in patients with relapsed/refractory epithelial endometrial
cancer (EEC), epithelial ovarian cancer (EOC), or carcinosarcoma (also known as Malignant Mixed Mullerian Tumor (MMMT)). As of
the cut-off date of December 30, 2019, 105 heavily pretreated patients had been enrolled across the six groups of the study. Approximately
67% of all patients had tumors with identified Wnt pathway alterations, which included approximately 20% with Wnt activating mutations.
Patients with EEC and carcinosarcoma had higher tumor DKK1 expression and a higher percentage of Wnt activating mutations than
the ovarian cancer patients. Patients whose tumors had Wnt activating mutations expressed 15 times higher levels of tumoral DKK1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Findings from the P204 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>DKN-01 single agent activity</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><B><I>Endometrial Cancer</I></B>: Twenty-nine EEC patients were enrolled in the DKN-01 monotherapy
arm, over 75% of whom had experienced three or more prior lines of therapy. Of those patients, 26 were evaluable for response.
In the 20 patients with a Wnt signaling alteration, one patient (5%) has an ongoing complete response, one patient (5%) had a partial
response, eight patients (40%) had a best response of stable disease, and 10 patients (50%) had progressive disease, representing
an overall response rate (ORR) of 10% and a disease control rate (DCR) of 50%. In the group of six patients without any Wnt signaling
alterations, one patient (16.6%) had a best response of stable disease and five patients (83.3%) had progressive disease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><B><I>Carcinosarcoma</I></B>: Ten patients with carcinosarcoma have been enrolled in the DKN-01
monotherapy arm, five of whom were evaluable for response as of the data-cut off date. Two patients (40%) had a best response of
stable disease, one of which has continued on monotherapy for nearly two years, and three patients (60%) had progressive disease.
Five patients had not reached their first tumor assessment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>DKN-01 plus paclitaxel combination activity</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><B><I>Carcinosarcoma</I></B>: Fifteen patients with carcinosarcoma were enrolled in the DKN-01
plus paclitaxel arm, six of whom were evaluable for response as of the data-cut off date. Two patients (33%) have had a partial
response, one patient (17%) has had a best response of stable disease, and three patients (50%) had progressive disease, representing
an ORR of 33% and a DCR of 50%. Nine patients had not reached their first tumor assessment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify"><B><I>Endometrial Cancer</I></B>: Twenty-five patients with heavily pretreated EEC were enrolled
in the DKN-01 plus paclitaxel arm. All of these patients had previously received paclitaxel, 44% had received hormonal therapies,
32% had received bevacizumab, 20% had received immunotherapy, and 12% had received a PARP inhibitor. Of those patients, 22 were
evaluable for response. A total of 12 patients (55%) have had a best response of stable disease, and ten patients (45%) had progressive
disease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Monotherapy Patients with Wnt activating mutations have longer Progression-Free Survival
(PFS) and Overall Survival (OS)</I>:</B> In a pooled analysis of all DKN-01 monotherapy patients, patients with Wnt activating
mutations have demonstrated a longer median PFS of 168 days as compared to patients without Wnt activating mutations with median
PFS of 56 days. Median OS has not been reached in the Wnt activating mutation group in the pooled analysis as compared to median
OS of 328 days in the non-Wnt activating mutation group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Monotherapy Patients with DKK1-high tumors have longer PFS and OS:</I></B> DKK1 expression
as measured by <I>in situ</I> hybridization RNAscope assay is currently available for 68 of the patients on the study, 32 of whom
were treated with DKN-01 monotherapy. Seven patients (22%) were identified as having DKK1-high tumoral expression. Consistent with
the results from Leap&rsquo;s study in patients with esophagogastric cancer, patients whose tumors are DKK1-high have prolonged
median PFS of 168 days as compared to patients with tumors that are DKK1-low with median PFS of 56 days. Median OS was 450 days
in the DKK1-high group in the pooled analysis as compared 276 days in the DKK1-low group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call Details:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. Dial-in Number:</B> (866) 589-0108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>International Dial-in Number:</B> (409) 231-2048</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference ID:</B> 1190677</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presentation will be webcast live
and may be accessed on the Investors page of the company's website at <U>https://investors.leaptx.com/</U>, where the presentation
slides and a replay of the event will also be available for a limited time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Gynecological Cancers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are numerous forms of gynecologic
cancers, but two of the most prevalent types are cancers of the uterus or ovaries. According to the National Cancer Institute,
there are more than 61,000 patients diagnosed with uterine cancer. There are currently very few post-surgical treatment options
for these patients, typically consisting of chemotherapy, local radiation therapy, and hormonal agents, and poor treatment outcomes.
Patients with endometrial cancers have a high frequency of mutations in a protein known as beta-catenin, with alterations estimated
at approximiately 30% of cases by The Cancer Genome Atlas. These beta-catenin mutations are often driver mutations leading to rapid
disease progression and poor outcomes. Carcinosarcoma, or Malignant Mixed Mullerian Tumor, is a uterine cancer comprised of carcinoma
and sarcoma cells and accounts for less than five percent of all uterine cancer. Carcinosarcoma is an aggressive tumor with poor
patient prognosis and poor response to chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About DKN-01</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DKN-01 is a humanized monoclonal antibody
that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling, a signaling
pathway frequently implicated in tumorigenesis and suppressing the immune system. DKK1 has an important role in tumor cell signaling
and in mediating an immuno-suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells
and downregulating NK ligands on tumor cells.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Leap Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leap Therapeutics (Nasdaq:LPTX) is focused
on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal
antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric,
hepatobiliary, gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01
in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit <U>http://www.leaptx.com
</U>or our public filings with the SEC that are available via EDGAR at <U>http://www.sec.gov</U> or via <U>https://investors.leaptx.com/
</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934
and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements
regarding expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of
future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments
from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties
include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing
campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues, the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials
may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug
product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining
and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding
factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC,
including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on March 16, 2020.
Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking
statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of
unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Douglas E. Onsi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leap Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">617-714-0360</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>donsi@leaptx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Heather Savelle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">212-600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>heather@argotpartners.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2016685d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2016685d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ / # 2(  A$! Q$!_\0
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M0^-;S1A8^$_-R(HC+-<ZB=:MH&88^TW>@VMDB@W]ZUG9$W9^L_B1X[TSX<^
M/%'C[58GN=,\,:#J&O7$4#!9;P6<1F@LX.O^D:E-Y%K:<$%[A0#@U^#>D?\
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M.7YC@,TPU'&Y;C,)C\%75XXK"2NG;SZM=FKEFBBBO0.T**** "BBB@ HHHH
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MM6NUR\!-V][]J)^XF 0 ;EYXY)[YYS^O;'ZTL:GEL 'GG/'./J/\CI3P_!V
MP_$]?BI5L9]=Q,7%X6_^QIV2;6E[O\'T8L/PCEN&XDK\3JKBGC\1&S7-_LFR
M3LO-*V]E=[WT^8/%?[(G[//COQ?<>._$?PXT[4/$EW=P7VHW2:KK]A9ZC=0?
M=FU30K'6+;1=1+9Q>"ZLW^W#B^^UGK]'6]I!:6ZV]O;QQ6\$45K%;Q(([>.&
M+]S###","$ 8"@9 (XK1P& 8, #U[D@XY!&#Z]A2;, X. ,=""Q_$?X#^8KW
MZ&7Y;@JU>K@L%A,-6QSOC983"86+QC6SQ323EVO>U]U<]_#9?@\).M7PV$P>
M'KXAWQ;PN%CA7BW_ -1323DUO??5][NS1117HG:%%%% !1110!4 CV#Y/E9C
MQ@9![$'J.N#G)Z]<YKY(_:7_ &2/ ?[1D5M?ZM<7'AKQKING_P!F:1XOL8?M
M,D-B+N:<:=JFF_:;6#5].^T7%Q<6MJUS:7EG=WER]C?(+N\#_7F,8 'S=_Z>
MWOG^M-<')P4'7YC@G/Y$COD<#TKSLSRS YMA*^ S*@L=@L1I+"O9]=][:Z/3
M[SAQ^6X'-<'5P&882.(P5=6EA9+1KS2:^31^>7[/W_!/_P !_!7Q%%XT\2>(
M9OB'XKTN:2Z\-RMI+:!I.B7)$G^G'2?[2U0WVH@L?L=Q=W)L[,%&L;-+VUM+
MP?BC\<[K6[SXS?%.X\2K)_;?_"?^)TU&%Y,^4(-7O8/)M\=;>UMH(+6RYYLX
M+;KDU_5J5(9F !) Q@8?M]XGL?PZ<<9Q\0?'[]A7X5_'#7[SQG'?:OX)\:ZA
MY<FJZOI!M[S3]9E@MX+.&;5-#O\ _1S.+>W@!N=*N=):[\I3?F\Y%?D_&_AQ
M]<X=P66\)8/"8=Y?C'C/J;Q7+]<>*7O/ZWB^:V*ZJ4GJGIY_EW&GAW]=R'!Y
M;PO0PF&_L_&?7/J;M_MCMK_M>+<K8OSD_N/Q>_9*?Q&O[2'PA/A7[0VJ#Q?:
MF\:VP<^'<S?\)1YP(QY!\,?VI]K[[L8Y(%?U"!=QSMP0A4?0^W'(S@?08[X^
M-?V<_P!C?X<_L^WDGB6QN+WQ5XV>SDT]O$>K&("PLIY5,]OHNEV_^CV/VHPP
M_:[FXN+R\)^T?Z<MG=75HWV6#@CGD?\ UN:^@\,N%LQX5R*KA\TDGC<?C)8U
MX1.\<)=)6NM';=[]$>[X<<+X_A?)*N%S%KV^)Q;QGU1-..$4E:R:T>S;WZ:E
MFBBBOTD_0@HHHH I*,<$ )]U0#GJ?7ZCO7Q]^V;\</&?P#^&6B>*_ \&CR:M
MJ?C6V\-S2:[9S7\$=A/H/B+5)YX(+?4+-A<?:=*LP,,WRFX_T0@C;]B\1X_N
M;0 2>=QQT/7(.?Y5^;G_  4]/_%C_"0XQ_PM#2/P/_"(>./>OH>$</A<?Q/D
MV$QE)8BAB<?@XXO"/[49-WCO]K9W?1^9\-XCX_&95P-Q)C\MKO 8[#Y1-X/&
M8;?"25M5Z>GHUU]\_9 ^*7B[XR?!?3_''C2XL[G7KS7==LG>QM(K"W6TL+WR
M8(HH8,C(QC>22V<'H,_4?7)8 # P".58@A0<\#@#K^5?!7_!/F[BL/V7],OK
MJ18;2SU[QG>74K\(MO!J+32RD]A]GP20.,9P3BOD+4_VB?VJOVH_'_B#2_V=
M!>^'/!WAQ,QQZ?<:/IDK6$UY>II6L^(M:U89M]7USR9EL]#M+OY5AN-UE>+9
MWFL#Z#&\(5LTXHXKH8&ME&393D^;8Q8O&8R7U+!8&+QCC@\)=)OF>RCJTE?9
MN_RF"\1,-P]P3P17S6EG'$&><09/@_J>#P.$>,QV<8M8+"XO&8OHOM7;>R/V
MU !89YX4X)SOXP,8_P#KC'YEH 1B%VJSDG &2^._/''3'!YXXYK\IOV4OVI/
MBK;?%>__ &?OVAIIIO%#7-U8:#JE[;:=%?V&NV,!GFT?59M'QIU]I^IV$,UW
MH^J+]J)N_LX-[>V6K6/V'H?V@_#/[=NM?%KQ.GPCU:_L/AILTQ_#<MKJ_@O2
M4CD_L?3/[5AW7%Q:ZW./[7-_BYNB  =H)&,^?4X+Q&%SEY1F.:9-EU&6"6.P
MF<8S&6R?&X1Z1EA,8E:2D]+VT:MHSU*/B=@,;PY0X@RK(LZS>M_:_P#8^-R;
M X-8K.,IQJTQ2QV$3OA5%>>MS]/&!VJ"%((R<\ ?0CGD>N>.WHNT$LY^48P>
M,\?U]^?J.:_(+]F3]I+X]^&_CW!^S_\ 'V6?4[K6+B73UFUC^S#JWA[5!H4^
MN:68-4T;%MK&GZY;B '_ (^^9[:]L;RTQ>65YF_M8?'C]HC2_P!HX_!SX4>+
M[S2[:]M_#%IH6CV%GX;@DN]8UJTAF'G:WJ]K]I'VB:88%SJMG:C'3.375#PZ
MS:6>/)/KN4:Y0\ZCF_UQ?V?B<G27^V1QB2=KZVWW?8XI^,F0QX8_UD_LW.=,
MY_U<Q>3_ %-_VQ@LY=_]CQ>#OH_T?S/U[N;.TGFM)KJVMYY;=]UI)-!#))#-
M@?O('()@X ^9,'CJ!P.9\7^/- \$GPV-<%QYGBOQ-IOA/2%L[5KGS-8U8M]F
M$^,"WM\0'=<<A>!MZ&OQN;]H7]LK]E_QAX=;X[1W^N^&]?DE+:3K;>&]3_M*
MPL+BR&J3^'?$.@7'^@:O:P7D)6VN[HV1\^V:\L^C#[X^._B"U\?^#/@!XD\$
MZR+>V\7_ !4\ ZGX;UU[0W7V%M5L[^72]1FTJX"FXFM;B:V:\TN[ R86LK\#
M.*\+B?A3&<,4:&.=? YC@,Q3^IYODV+^N8+%N+2E&,DK?6U?X9+F^2:7N\'\
M>Y5Q;5S'!4<'F^3YKEMO[6R?.<']4QV#6,7^QXMX5W<L&[7O?57OKJ?;(.1D
M=Z\1^"OC37_&VG>.KS7YHII=#^)OBWPQIGV>VAMXH='TG["+&+$&?M&/M$W^
ME7/S'C/05=\&^$_BOI&MB\\7_%RV\8:+]FN8WT6'P!H_AN1KJ8GR)_[4L-2O
M+@&UR1]GQS@<D8Q\V?"/PE\4/$X^)K>$OBA#\/\ 0+?XN>.T^S6GA+3M?O[_
M %,WED9YKV?4+BT6W@^S_8?L8M#D@7&<<&OF'.?/2_=;]>WH?H!]ZT5\T_#;
MQSXWTKXA:M\'/B;J&EZ]KEEH,7B;PQXOTZS&E2>)]%EO3!.+W2H/]%M]1M<%
M2+7'_'C<Y-Y@7EWD6^N?%#XV:QK5QX!\80?#OX8:'J5UI6C^*K#1[/7-;\;:
MI9>1!?300:A<_9K?P_:W G%E=VOV0WAZ_;!_QYU[:%O=M]VGX ?5M%?.OPX\
M:^,]+\;ZI\(OB;?6>N>([?1X_$WA7Q;IUE_9\'B;PY]LGL+@ZI8P_P"BZ=K%
MI<6__'K:@JP^TXS]E^V7G#>"K+XZ?%7P[;^.H_C3'X-MM6O-973O#VC^ ]!U
M"RTV+2]8O]*(GOM0N?M-S_QY<_:_M8&0<GI3]HOL6L@/L.BO#?%/@?XKZ[>:
M?_8_Q@?PGI5IHMA;WD-CX3TC4;S5=>@,YU34Y[BX^R_9[>Y_<%;2TP /M &W
MBL'X:^+_ !MI7CO7/@_\1=8L_$>MVFB1>,/"OBRRL(-._M[PO/>"QFAU6Q@_
MT:WU"TN<?\>V1>@70^UG[(+N\7M/?Y)4OR8'TA17Q5X ?XV?&33]8\66_P 8
M_P#A![.W\3ZSH.GZ#H_@/1M0@BBTJ8 33WVHW7VFX)\_Z<8S7HO@7QYXXT#Q
MHGPL^+?]DW&N:CI]SJ'@;Q9HT1MK;QM;6'GSZI#?62_Z/IVL6MM_I)M0+2S(
M%R .+.[O:A4YGLOZ^\#Z0HKY2M]=^*'QLUC6Y_ /B^W^'?POT/4KK2M'\56.
MCVFN:WXTU2Q\B"]FAAU"Y^RV_A^UN!.+*[MOLAO/^GP?\>?1_#CQKXTTOQKJ
MGPB^*%[9ZUXDM](C\3>&/%FFV7]GP>)_#AO)["X-]8P#[-IVL6MQ;_\ 'K:C
M!'VG@BT%Y>Q[;^K/_,#Z*JK++'#%+)(0$CCEE?'_ #R@Z\<^W/ZUY5\$_$^M
M^,?A;X2\3>(+I;S6-4M[]]0N4MX;,SR6^KW]E"1;VZVUO ?LT$.  ">Q]>6L
M?&?B2[^-OQ%\#SWGF^&]&\ :7K&FV'V.SC>&_OA )YOMOV87%Q_KYLK<W6 >
M0.,U2J0Y:4^E>UON ]2\">-M$^(?A?3_ !AX=-TVCZJ]^EG)>6WV:X?[!J5Q
MI4Y\DDX'VFQG&,GZ\UE:=XE\4WGQ#\2^%;OP5J%CX5TS2;"\TGQQ)>P_8M7O
MY_L1N-.M[(?,#;"XG&<G']E7'VU?]+M,_)O[.O@_XOZI\(O"]]X3^,%GX3T2
M:;7S9:#-\.M!U^2S\CQ)JL$X_M6XU.TN+@75QY]W@_\ 'IYYLAG!Q]!:1XYU
M:Q^(_P 3-$\3ZY$?#/@KP3X-UY[E[.TLH[.2XM-6G\0ZE--;VQN!!<BQ^TFV
M-U=BT (LL#@13J2Y*4Y]2>:/?\SWNBODG1)?C9\9H6\8:5XXA^%'@:\>7_A$
M+#3?#UGK^N:]I?FW!@UG7)]0N -/-W!Y!L[6V Z_\>72[O=7Q9K'Q5\,67P[
M^&EGXPTC5/'_ (]UOQ';#XA:EX?L[.WL-!\.PC5)YX="MQ_9MQXA&G36XLK4
MC['=W<%UG'-X#VFG/[)_J4?4-%>(^$?!/Q3\->(;.\U[XOW/C;PV]M<QZEH^
MJ>$M&TNY%T8?]"GL;_3R+D!9^6M3D8.!NS@^W5O&2DKH"MCY,A3SU&!P>.W3
MICK[\9K\X/\ @IQ!<3_ _P )B**23R?B7I=S-L3>8XH/"'C?SI<=L#/OSBOT
MB(+(,'&,D_GGISV_P)KD?&/A#PSX]T&_\-^*])M];TG4;:ZMKBSO4/\ JKVT
MN-/N/(EAQ<VTIM[N>U^UVA6[M1,2K#=NKU\@S.&3YWEF:U:7MZ.7XR.,:3W4
M6_=U[IOY(^7XQR*KQ-PSG.0T:_U>OF.#>#^M]F[:Z:OOZL_-?]B_7]"\6_LE
M>-?A;H>OZ:WQ 71_B27\-+=PC7X(=:CGAL=1ATS/VFXT\7&JV-N-3M;469O9
MOL)S?9!_/C]FS1K/7M5\2>'KO]I76/V=+P"QG@^;4]+TOQ!+!Y\,\%[JMMXL
M\*:=I^H:9^X^QVNI\WGVZY&GAOLEX*_;;X+?LE_"OX$>,-<\9>!3XBBN]<T>
M71&L-6U6#4-/L]/FO;+4VBL3_9]MJ&/M%C <7=Y>''RXSBN*^*?[!WP%^)^N
M7?BBXL-;\*:[J<\EYJMWX1U*"QMM2O)YA<7%[/I=_I^JZ:;B[F_X_6M;.U-V
M<LP:[!8?IN'XZR*AF?%<85,=1R_B/&8/,%CE@,!B\9@<9%)XJ#P.-^MX66%;
M;M]KHW#1GX9F7A9Q;C<DX#G.EDV(S3@[!XS)\9D[QN,P>"SC!6^JX3&8/&X/
MZIC,%C++OI?0^7OA!^RUX/N/CAX>\;V'[7/A_P"+WC+PW=VOC#4]+L[2#6=;
MU*QT/[#8@7^JP>/_ !!=VT'[ZPMOM-T+Q3NM@+0G('S_ *1X\^(/[4'Q\\7:
M)XY^..M?!+P_!'KMUI6E/K]YINC6']DZE9:58>'(;*?6?#^G#7_L\\]U>75R
MIO+PZ7J?^@@9-E^G_P $OV-/A1\!_$S>,?"EYXLO]>?3I],^U:_KD%Q$EI>&
MW>XA^PZ5INDV]QDVT !NUNL&('(.#7/_ !._82^!'Q2\2ZKXNU&T\2>'=>UN
M[?4-6NO"NL16<&H7]SGS[J:QU#3=6M()[G'VF[:TM[3[7>'[=)NOKAI&SP_&
MN3_VMC:V89EC\Q:R?!X')LYEDV3?7,HDIMXKER>RP+PK3<8M6E9=+N^F(\,.
M)/[!RRCE669/D]\ZQF;<2<-X/B/.?J6<X1X/"8/!K&9SB_KF-^N*VO1Z>9^;
M/@;PK'X+_;K\ >&X_B#<?%"/3]>T<P^,[R]&H7%^)_"OG_8_/_M'5?\ D&^?
M_9F/M9'[CK:=:[W]HO6=+\/_ /!0KPIKFMWMOI6E:7K?PQO+^^OI1;V=G8P6
MD,T]Y<3MC[/!;=3N/4\U]V?#']A#X)_"OQ;HGC719?&6JZ[X?N3?Z4VMZ]9R
MV\-UY$\'FFWT_3-+%P<7!XNLCV/(KX"_:?\ "VD^-/V]=!\'^((Y;C1_$=_\
M.](U*&&:>WN'L+ZTAAF\B>WY@G'GC!)Y'O7T66<1Y/Q%Q%S4JV-KX;+_  _S
M# X_%_4L#@\9B[)/&8S"X.+>#3M*5HJUTF]&?)YUP?Q#P?P?1AB<'D^'QV8>
M*N39SD^#P>,QN,P6#UM@\'C,;C/]L>JM]<U:.]_X*.?%WX9>.?"WPX\/^#/%
MGAOQAJEGKU]J]W=>&]9T[6(M,L!IOV P7M]87%Q;0?VG<WT'^C_:06%CSG Q
M[=X>T;4_#7[.7['=IKJ2VUQ:?$_X?7URMVHMY+"UU.;7-:LH+TW&3!]CL9X@
M0>0T!Z9Q7=>#O^">7[/OA+Q!:>(3;>)_%#Z?=Q7]GI?B;6X+W1X[J"?SH?M%
MCI^GZ6=0MUP0UKJEU>65YD?;[2[[?7'C;P'X<^('AVY\,>)[(W>FR317"&.X
MDLY[2[MC_H]W936Y#V\]M\QC(SC)+9/!_-.)\_RBOPQD_"N1?7<10R_%XS'8
MS&XU1P3>,FY6C&,')J,5BK)MN^B5]6?L7!?"/$E/BW/N.>*EE& QV;X+!Y1A
M,HR?&8S&8/ZG@_JC6,Q>,:3<F\)HHI)+=ZV/0:^:OV9?^0%\3Q_U6_X@?J=+
M_P *[KPY\+(M"U:SU>;QY\3/$DMA'(+2Q\4>*OMVEI+-9SV1GGL;?3K2"_N?
M(N)PMU=F[*GGM70>#/ ^C^!K37+/1/M?E^(/$>J>*;_[?+]H_P")IK9@-\82
M+>U'V?, *VV/EYYR<5\#[\ITG\V?L)\\>.(&G_:M\ PQ?)<WGPI\3VR/[D^*
M1#^&22:\[_9[^&%_KWP_CM3\5_BCX/UGP[K6OZ)X@\'Z#KMGI]MX?U.#6+[,
M']EW&FW=Q:_:K:>WNSDC-W-<]<''V'??#S0=1^(&B_$BY^W_ /"1:#H]UH6G
MQI<1?V?]@O?MOG^?!]FRUQF^N,,+H<8 ![\YKGP3\+ZOXFO/&6F:IXL\&>*-
M3ABAU76?!FOS:1)K$4'D>2-5LI[:\TVX*_9X,YLP2(1R3FH]A/GY]+D<GG^'
M_!,7PK\#+?PWXVT_QWJ'C_QYXOUC3-+OM'LO^$KU6QU"-+"^&9XN-.M;C@_Z
M3_Q]<$<#')L?LT?\D8\)_P#7UXM_]3;Q)7:^#_!$7A&74I_^$G\9>*+G5/LB
M37/B_7&U>2UBLC<""&QA%M:6U@,WTY86UK_I1 8]C6IX*\)Z7X&\.V'A?1_M
M/]FZ:]_):_:Y?M%S_P 334KW5)S/-]GM]Q^U7LY& ., \CG>-/EFY7+/G2RT
MSQ1\:/&?Q(^U_$WQAX*\,>"?%LW@_3/#'@348=$UB6;2[.QGFU[5M5%O=7'V
M?4[B><65K]E&?)N1NS:YK$\)^$)/!7[4EOI<OBSQ9XO63X,W-_#J7C35/[9U
MBWBN/&,\']FV]]]FM?\ 0+8P?:ER.L]P!7M>M_!/PWJ?B:_\9:9KGC#P9XDU
MF**+6[_PAKW]EG6!!%#!;B_L;BVU33;C:( /^/0D=\D$FYX7^$>A^'/%+>-I
M=<\7^)_$IT63P['JOBS7O[5D@T::\%\;."""UL[86XN<W(X)S/<]S@8>QGS?
MA_7];D<GGU[?\$\[_9-/_%M]<'I\1?&6/^_]O6?\8H)/$7QM^"'A_1=TFJZ/
M!X[UW59K?,DFCZ->Z/964$U\"-MO;ZG<0SV@:X'-Y]E7_EYY\_\ V>/AC:>(
MO".N^(+/Q=XY\)ZI/XX\46E_-X2\1FPM[^*QNXA ;ZQO[;5M-:XM3-.!<"T5
MN3SD@5]/^!_A5X8^'][J^JZ6VL:GK^ONCZ_XF\1:E-K'B#5A /W$-Q?7&+=8
M%/ MK6UM%(-OD9M5*J,95:-*/X^G^0H^_!=/ZT/DW]GWX8ZAXA^'L-H?BS\4
M?"&L>&]5U[1/$/@S0=>LM/M_#VJ0:S?3F'[#_9UU<V_VFVG@NSG!:[GN=H)!
M%?0_A+X&6_AOQKI_CO4/'_CSQ?K&FZ5?:/9?\)7J=EJ$4=A??ZZ+C3;6Y W#
M[1_Q]$[AT*XSJZW\$_"^K^)KSQAIFJ>+/!GBC4H8H=5UCP9KTVD2ZO'!Y'DC
M5;*XMKO3;DKY$ .;($B$ G.<]1X0\$1^#Y=1N/\ A)_&7BBZU,VJ377B_76U
MB2VBLC<B"&RA%M:6UADWLY86MKFZX+=0:JG3Y5R2I?-!&/5_+_,\Y_9BO;6Y
M^#OARQCDCDO?#]UKNAZM;*X^T:=J5EK^IEK.]@Y^SSFWG@N0" ?LD]OU4K7.
MZ*OF?M._%>,8;S?A=H*(G]\DV. #[DX]^.O%=O>_ SPT==UCQ%X<\0^./ FH
M>([S[?XA3P;XD_LZSUF_S/-]LOK'4+75;;S]T\W-H+08GN#T-;?@OX3>'O!F
MMZCXGM]5\3Z_XDU>PBTV_P!;\3ZY)J]Y-802PRPP?\>]K; #R(ONVN[@C.,Y
MKV<N6E'_ )\6U[Z=/D:>]_7,>>?LDON^ O@^//[RWN_%,,R=##-_PE6N3^5*
M>Q GAR/<9]*XSQGI.H:[XU_:?TG28+BZU*^^$/A:&SL[9?,N+VZ_LS7?(LX(
M3G,]WG[+SWG'->KS? O0X=1UC4?#WB_XC>#H/$&HW>LZIH_A/Q0-+T>;5+[!
MOKR"RFTV]_L^XNB!DVEU:<GCI79^'_ &A^&-9U#Q!IKZI)J&H:!X<\.7+W]\
M;SS+'PK#/;Z7*9I_]*GOS]H/VVZNKIOM><D<8,^SER4:,P_N_A^!@? C6-/U
M?X0_#I].FAE^P^$M!TB\CBDW_9M3TG3+>QO[28=8)Q<PS Y_7*@]!X[^''AO
MXBZ3#I7B2"Y=K.ZBO](U6QNIK#6-$U2#B#4=+OK<9M[A<\_\NIP-UJ:XNX^
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M_+/:.***Z,.VI.S:]'Y'F9M"#I:QB]MTGO8]* P,#M2T45SGIA1110 4444
M%%%% !1110!AV&C:1X=M4M-#TK3=(M9+U)GMM-T^SL+=KBY=5N+DP6<$$)N)
CQ_K)MFYCWQQ6Y110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
